Press Releases

Analysis Process Under Way For Data Monitoring Committee’s Assessment BETHESDA, MD, December 10, 2013 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the number of events required to trigger the first interim analysis of its Phase III clinical trial in patients with Glioblastoma multiforme (GBM) brain... Read More

Presentation by CEO Linda Powers To Be Webcast Live BETHESDA, Md., December 5, 2013 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that CEO Linda F. Powers will present at the Oppenheimer 24th Annual Healthcare Conference. The Conference will take place on December 10th and 11th at the Crowne Plaza Hotel in... Read More

BETHESDA, Md., November 25, 2013 — Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, has completed an underwritten public offering of 4,895,834 units at a public offering price of $4.80 per unit, resulting in gross proceeds of $23,500,000. Northwest also announced today that the underwriter has exercised in full its option to purchase an... Read More

BETHESDA, Md., November 20, 2013 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today the pricing of an underwritten public offering of 4,895,834 units at a public offering price of $4.80 per unit, resulting in gross proceeds of $23,500,000. Each unit consists of one share of common stock, and a warrant to purchase 0.5 shares... Read More

NYU’s Dr. Marc Siegel Discusses DCVax And Its Life-Extending Potential As A Cancer Therapy BETHESDA, MD, November 8, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that their vaccine was featured yesterday in news coverage on both Fox News and Fox Business News. The segment was hosted for Fox by Dr.... Read More